跳至主要内容
临床试验/NL-OMON50293
NL-OMON50293已完成不适用

Preoperative Image-guided Identification of Response to Neoadjuvant Chemoradiotherapy in Esophageal cancer - PRIDE study

niversitair Medisch Centrum Utrecht0 个研究点目标入组 200 人开始时间: 待定最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
200

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
18 至 99(—)

入选标准

  • Histologically confirmed squamous cell carcinoma or adenocarcinoma of the
  • esophagus or gastroesophageal junction (i.e. tumors involving both cardia and
  • esophagus on endoscopy)
  • Potentially resectable locally advanced esophageal tumor (cT1b-4a N0-3 M0):
  • based on standard primary staging by EUS and 18F-FDG PET-CT
  • Scheduled to receive neoadjuvant chemoradiotherapy according to the
  • CROSS-regimen: weekly administration of carboplatin and paclitaxel for 5 weeks
  • and concurrent radiotherapy (41.4Gy in 23 fractions, 5 days per week) followed
  • by esophagectomy
  • Age > 18 years
  • Signed informed consent

排除标准

  • Patients who meet exclusion criteria for MRI
  • Patients who meet exclusion criteria for intravenous gadolinium-based
  • o Glomerular Filtration Rate (GFR) of <30 mL/min/1.73m2
  • o Nephrogenic Systemic Fibrosis (strict contra-indication for gadolinium-based
  • o Known allergy for gadolinium-based contrast
  • Patients with a blood plasma glucose concentration >10 mmol/L or poorly
  • controlled diabetes mellitus
  • Irradical endoscopic mucosal resection (EMR) or endoscopic submucosal
  • dissection (ESD) of primary tumor prior to start of neoadjuvant
  • chemoradiotherapy
  • Pregnant or breast-feeding patients

研究者

发起方
niversitair Medisch Centrum Utrecht

相似试验